Follow

CS Medica A/S

Spotlight Stock Market (Sweden)

CS Medica fully owns two Denmark-based subsidiaries: Galaxa Pharma A/S and CanNordic A/S, whereby CanNordic A/S is a registered Medical Device product developer and Galaxapharma A/S is a product distributor in the Nordic Region.
Go to market

Sector:
HEALTH CARE
Media
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
CSMED
DK0061668225
Spotlight Stock Market
Sweden (SE)
Details of share in CS Medica A/S with ticker CSMED
Status
Active
Currency
SEK
First trading date
14 Sep 2021
Directed issue
Sign in to buy
Exercise
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Market move
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
CSMED
DK0061668225
Spotlight Stock Market
Sweden (SE)
Details of share in CS Medica A/S with ticker CSMED
Status
Active
Currency
SEK
First trading date
14 Sep 2021
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Market move
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
CSMED TO1
DK0061668308
Spotlight Stock Market
Sweden (SE)
Details of option in CS Medica A/S with ticker CSMED TO1
Status
Archived
Currency
SEK
Trading period
14 Sep 2021 - 30 Aug 2022
Terms
Update (09.09.2021): First trading day for warrants TO1 is September 14, 2021.
Exercise
Sign in to buy
People
Lone Henriksen
CEO
Jørgen Flemming Ladefoged
Chairman of the board
Stein Løkstad
Board member
Anders Permin
Board member
Gitte Henriksen
Board member
Company Details
Sector
HEALTH CARE

Address
Fruebjergvej 3
Zip code
2100
City/district
Copenhagen
Country
Denmark (DK)
Registration number
33871643
LEI code
549300SC8KWO7JFWLN17
First trade date
14 Sep 2021
Registration date
17 Aug 2011
Short name
CSM

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More